Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04895696 · ClinicalTrials.gov registry record · Phase 2

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

A Phase 2 study of Systemic Lupus Erythematosus, sponsored by Bristol-Myers Squibb.

Active
Registry status
Phase 2
Development phase
268
Enrollment target
20
Study locations

NCT04895696 is a Phase 2 study of Systemic Lupus Erythematosus that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 268 participants, below the 378-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04895696, a Phase 2 study of Systemic Lupus Erythematosus, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
268 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythematosus (SLE). The extension period will provide additional long-term safety and efficacy data and enable those participants initially randomized to placebo to receive treatment with Afimetoran.

Conditions Studied

Systemic Lupus Erythematosus

Interventions

  • OTHER Placebo
  • DRUG Afimetoran

Study Locations (20)

Florida

  • Local Institution - 0121 - Clearwater
  • Local Institution - 0167 - Kissimmee
  • Local Institution - 0122 - Orlando
  • Local Institution - 0173 - Ormond Beach
  • Local Institution - 0154 - Plantation
  • Local Institution - 0137 - South Miami
  • Local Institution - 0155 - Tamarac

California

  • Local Institution - 0123 - Huntington Beach
  • Local Institution - 0170 - La Jolla
  • Local Institution - 0159 - La Palma
  • Local Institution - 0172 - San Diego
  • Local Institution - 0164 - Woodland Hills

Georgia

  • Local Institution - 0160 - Atlanta
  • Local Institution - 0205 - Suwanee

Alabama

  • Local Institution - 0100 - Birmingham

Illinois

  • Local Institution - 0146 - Orland Park

Kentucky

  • Local Institution - 0187 - Hopkinsville

Louisiana

  • Local Institution - 0171 - Baton Rouge

Maryland

  • Local Institution - 0134 - Wheaton

Trial Details

FieldValue
Enrollment Target 268 participants
Start Date 2021-10-11
Est. Completion 2029-04-22
Phase Phase 2

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04895696

The ClinicalTrials.gov registry entry for NCT04895696 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 268 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 378-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (29% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04895696 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT04895696 about?

NCT04895696 is a clinical study titled "A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)". The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythematosus (SLE). The extension period will provide additional long-term safety and efficacy data and enable those participants initially randomized to plac...

What is the current status of trial NCT04895696?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 268 participants. The study started on 2021-10-11. Estimated completion is 2029-04-22.

What conditions does trial NCT04895696 study?

This clinical trial studies the following conditions: Systemic Lupus Erythematosus.

What interventions are being tested in trial NCT04895696?

The interventions under investigation include: Placebo (OTHER), Afimetoran (DRUG).

Who is sponsoring clinical trial NCT04895696?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04895696 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Systemic Lupus Erythematosus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Systemic Lupus Erythematosus

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.